NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

MGC Pharmaceuticals Limited (LSE: MXC)

 
MXC Technical Analysis
4
As on 3rd Jun 2024 MXC SHARE Price closed @ 21.00 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.76 & Strong Buy for SHORT-TERM with Stoploss of 0.57 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

MXCSHARE Price

Open 21.00 Change Price %
High 22.00 1 Day 0.00 0.00
Low 20.00 1 Week 0.00 0.00
Close 21.00 1 Month -1.00 -4.55
Volume 264 1 Year 20.32 2988.24
52 Week High 65.00 | 52 Week Low 0.06
 
LSE UK Most Active Stocks
PREM 0.04 -20.00%
TRP 0.03 50.00%
UKOG 0.01 0.00%
DEMG 0.02 -50.00%
SYME 0.00 %
ORCP 0.02 0.00%
WBI 0.04 0.00%
SMDS 582.50 0.00%
DKE 0.15 0.00%
NNN 0.09 50.00%
 
LSE UK Top Gainers Stocks
0YY7 20.40 280.60%
SSIF 18.50 208.33%
CGW 55.03 107.66%
GILD 0.08 100.00%
GILD 0.08 100.00%
GILD 0.08 100.00%
CNN 65.00 85.71%
0A4Y 0.05 66.67%
VENC 139.60 65.21%
CMO 5.50 57.14%
 
LSE UK Top Losers Stocks
DNA 0.06 -99.90%
DNA 0.06 -99.90%
DNA 0.06 -99.90%
DNA 0.06 -99.90%
JPE 12.55 -98.66%
SPPC 0.15 -93.75%
0M09 281.40 -89.74%
AGM 1.00 -80.95%
AGM 1.00 -80.95%
AGM 1.00 -80.95%
 
 
MXC
Daily Charts
MXC
Intraday Charts
Whats New @
Bazaartrend
MXC
Free Analysis
 
MXC Important Levels Intraday
RESISTANCE24.85
RESISTANCE23.62
RESISTANCE22.85
RESISTANCE22.09
SUPPORT19.91
SUPPORT19.15
SUPPORT18.38
SUPPORT17.15
 
MXC Forecast April 2025
4th UP Forecast21.56
3rd UP Forecast21.38
2nd UP Forecast21.27
1st UP Forecast21.16
1st DOWN Forecast20.84
2nd DOWN Forecast20.73
3rd DOWN Forecast20.62
4th DOWN Forecast20.44
 
MXC Weekly Forecast
4th UP Forecast21.33
3rd UP Forecast21.22
2nd UP Forecast21.16
1st UP Forecast21.09
1st DOWN Forecast20.91
2nd DOWN Forecast20.84
3rd DOWN Forecast20.78
4th DOWN Forecast20.67
 
MXC Forecast2025
4th UP Forecast146.16
3rd UP Forecast106.02
2nd UP Forecast81.21
1st UP Forecast56.4
1st DOWN Forecast-14.4
2nd DOWN Forecast-39.21
3rd DOWN Forecast-64.02
4th DOWN Forecast-104.16
 
 
MXC Other Details
Segment EQ
Market Capital 64196336.00
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Offical website >
 
MXC Address
MXC
 
MXC Latest News
 
Your Comments and Response on MGC Pharmaceuticals Limited
 
MXC Business Profile
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company develops CannEpil, an oral solution to treat refractory epilepsy; Cognicann for the treatment of dementia and Alzheimer's; InCann to treat Chron's and colitis; Tetrinol for the treatment of cachexia; TopiCann to treat dermatitis, rosacea, seborrheic dermatitis, and psoriasis; and CepaCann for the treatment of cerebral palsy. It is also developing phytocannabinoid ratio products, such as MP 100, MP 1:30, MP 1:1, MP 7:1, MP 15:1, and MP 25T. In addition, it develops CimetrA, which is in Phase III for arresting the cytokine storm in COVID-19 patients; and ArtemiC, which is in Phase II clinical trial for the treatment of COVID-19. It has partnership agreements with Royal Melbourne Institute of Technology, the University of Notre Dame, and the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia. Address: 1202 Hay Street, West Perth, WA, Australia, 6005
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service